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Human T cell leukaemia virus type-1 (HTLV-1), the first
pathogenic retrovirus discovered in humans 29 years ago
is the causative agent of two major diseases: a rapidly fatal
leukaemia designated adult T-cell leukaemia (ATL) and a
neurological degenerative disease known as tropical spas-
tic paraparesis (TSP) or HTLV-1 associated myelopathy
(HAM). Approximately 5% of HTLV-1-infected individu-
als develop malignancy after 40 to 50 years of latency. The
viral transcriptional activator and oncoprotein Tax-1 has
been the major focus of scientific investigation because of
its numerous and crucial roles in the pathogenesis of
HTLV-1-induced diseases.
One of the most immediate responses to cellular stress
such as viral infection, oxidative stress or UV, is a reversi-
ble block of mRNA translation. To achieve this, the cell
sequesters mRNA in specific cytoplasmic structures called
stress granules. Because mRNA coding for stress respon-
sive proteins are not sequestered in stress granules, this
mechanism allows the cell to focus on responding ade-
quately to the stress stimulus. Stress granules are charac-
terized by the presence of specific proteins, G3BP, Tiar and
Tia-1. Recently, the class II histone deacetylase HDAC6
was identified as a critical component of stress granules.
Indeed, deletion of HDAC6 impairs formation of stress
granules.
It is well known that Tax-1 accumulates in the cytoplasm
under stress [1]. We have observed that in stressed cells,
cytoplasmic Tax-1 concentrates into 'Tax-1 cytoplasmic
structures' that we identified as stress granules. Indeed,
upon stress, Tax-1 colocalizes with G3BP and Tiar, two
specific markers for stress granules. Moreover, we have
shown that Tax-1 is able to inhibit stress granule forma-
tion. By screening various stress granules components, we
have unravelled a specific interaction between Tax-1 and
HDAC6. Deletions analysis demonstrated that the interac-
tion is mediated by the ubiquitin binding domain of
HDAC6 and the zinc finger region of Tax-1. Interestingly,
a Tax-1 mutant deficient for binding to HDAC6 still local-
izes to stress granules upon stress but proves unable to
inhibit stress granule formation.
Our results thus demonstrate that Tax-1 impairs stress
granules formation by interfering with one of their key
components. By preventing stress granules formation, Tax
could prevent adequate management of the stress by the
infected cell, which could participate in cellular transfor-
mation processes. Our findings thus unravel a new strat-
egy developed by HTLV-1 and we postulate that this new
function of Tax might have important role in HTLV-I-
induced transformation and oncogenesis.
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